
# World Journal of *Gastroenterology*

World J Gastroenterol 2024 March 7; 30(9): 994-1260





Published by Baishideng Publishing Group Inc

WJG

# World Journal of Gastroenterology

#### Contents

#### Weekly Volume 30 Number 9 March 7, 2024

#### **EDITORIAL**

994 Role of exosomal circular RNAs as microRNA sponges and potential targeting for suppressing hepatocellular carcinoma growth and progression

Papadopoulos N, Trifylli EM

999 Role of albumin-bilirubin score in non-malignant liver disease

Xu SX, Yang F, Ge N, Guo JT, Sun SY

1005 Early prediction and prevention of infected pancreatic necrosis

Lv C, Zhang ZX, Ke L

1011 Impact of microplastics and nanoplastics on liver health: Current understanding and future research directions

Chiang CC, Yeh H, Shiu RF, Chin WC, Yen TH

#### **GUIDELINES**

#### 1018 National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma

Dar FS, Abbas Z, Ahmed I, Atique M, Aujla UI, Azeemuddin M, Aziz Z, Bhatti ABH, Bangash TA, Butt AS, Butt OT, Dogar AW, Farooqi JI, Hanif F, Haider J, Haider S, Hassan SM, Jabbar AA, Khan AN, Khan MS, Khan MY, Latif A, Luck NH, Malik AK, Rashid K, Rashid S, Salih M, Saeed A, Salamat A, Tayyab GUN, Yusuf A, Zia HH, Naveed A

#### REVIEW

1043 Diseases of bile duct in children

Eiamkulbutr S, Tubjareon C, Sanpavat A, Phewplung T, Srisan N, Sintusek P

1073 From liver to hormones: The endocrine consequences of cirrhosis

> Quiroz-Aldave JE, Gamarra-Osorio ER, Durand-Vásquez MDC, Rafael-Robles LDP, Gonzáles-Yovera JG, Quispe-Flores MA, Concepción-Urteaga LA, Román-González A, Paz-Ibarra J, Concepción-Zavaleta MJ

#### **MINIREVIEWS**

1096 Prediction, prevention and management of gastroesophageal reflux after per-oral endoscopic myotomy: An update

Nabi Z, Inavolu P, Duvvuru NR

#### **ORIGINAL ARTICLE**

#### **Clinical Trials Study**

1108 Clinical manifestation, lifestyle, and treatment patterns of chronic erosive gastritis: A multicenter realworld study in China

Yang YY, Li KM, Xu GF, Wang CD, Xiong H, Wang XZ, Wang CH, Zhang BY, Jiang HX, Sun J, Xu Y, Zhang LJ, Zheng HX, Xing XB, Wang LJ, Zuo XL, Ding SG, Lin R, Chen CX, Wang XW, Li JN



World Journal of Gastroenterolo					
Conter	nts Weekly Volume 30 Number 9 March 7, 2024				
1121	Detachable string magnetically controlled capsule endoscopy for the noninvasive diagnosis of esophageal diseases: A prospective, blind clinical study				
	Yang YL, Qin HW, Chen ZY, Fan HN, Yu Y, Da W, Zhu JS, Zhang J				
1132	Melanocortin 3,5 receptors immunohistochemical expression in colonic mucosa of inflammatory bowel disease patients: A matter of disease activity?				
	Gravina AG, Panarese I, Trotta MC, D'Amico M, Pellegrino R, Ferraraccio F, Galdiero M, Alfano R, Grieco P, Federico A				
	Observational Study				
1143	Double-nylon purse-string suture in closing postoperative wounds following endoscopic resection of large (≥ 3 cm) gastric submucosal tumors				
	Wang SS, Ji MY, Huang X, Li YX, Yu SJ, Zhao Y, Shen L				
1154	Recent trends in the epidemiology and clinical outcomes of inflammatory bowel disease in South Korea, 2010-2018				
	Kim S, Lee HJ, Lee SW, Park S, Koh SJ, Im JP, Kim BG, Han KD, Kim JS				
	Prospective Study				
1164	Staging liver fibrosis with various diffusion-weighted magnetic resonance imaging models				
	Jiang YL, Li J, Zhang PF, Fan FX, Zou J, Yang P, Wang PF, Wang SY, Zhang J				
1177	sTREM-1 as promising prognostic biomarker for acute-on-chronic liver failure and mortality in patients with acute decompensation of cirrhosis				
	Yu SM, Li H, Deng GH, Wang XB, Zheng X, Chen JJ, Meng ZJ, Zheng YB, Gao YH, Qian ZP, Liu F, Lu XB, Shi Y, Shang J, Chen RC, Huang Y				
	Basic Study				
1189	Uridine diphosphate glucuronosyltransferase 1A1 prevents the progression of liver injury				
	Jiang JL, Zhou YY, Zhong WW, Luo LY, Liu SY, Xie XY, Mu MY, Jiang ZG, Xue Y, Zhang J, He YH				
	SYSTEMATIC REVIEWS				
1213	Treatment of <i>Helicobacter pylori</i> with potassium competitive acid blockers: A systematic review and meta- analysis				
	Kanu JE, Soldera J				
	SCIENTOMETRICS				
1224	Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis				
	Li HY, Zheng LL, Hu N, Wang ZH, Tao CC, Wang YR, Liu Y, Aizimuaji Z, Wang HW, Zheng RQ, Xiao T, Rong WQ				
	CASE REPORT				

PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal 1237 adenocarcinoma: A case report

Kong YH, Xu ML, Zhang JJ, Chen GQ, Hong ZH, Zhang H, Dai XX, Ma YF, Zhao XR, Zhang CY, Chen RZ, Xing PF, Zhang LY

#### Contents

World Journal of Gastroenterology

#### Weekly Volume 30 Number 9 March 7, 2024

#### **LETTER TO THE EDITOR**

1250 Genetic risk stratification of inflammatory bowel disease-associated venous thromboembolism: An Asian perspective

Huang JG

1253 Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis

Colapietro F, Pugliese N, Voza A, Aghemo A, De Nicola S

Exploring non-curative endoscopic submucosal dissection: Current treatment optimization and future 1257 indication expansion

Zhu YN, Yuan XL, Liu W, Zhang YH, Mou Y, Hu B, Ye LS



#### Contents

Weekly Volume 30 Number 9 March 7, 2024

#### **ABOUT COVER**

Editorial Board Member of World Journal of Gastroenterology, Pal Miheller, MD, PhD, Assistant Professor, Department of Surgery, Transplantation and Gastroenterology, Head of Gastroenterology, Semmelweis University, Budapest H-1088, Pest, Hungary.miheller.pal@semmelweis.hu

#### **AIMS AND SCOPE**

The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

#### **INDEXING/ABSTRACTING**

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The *WJG*'s CiteScore for 2021 is 8.3.

#### **RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Hua-Ge Yu; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Gastroenterology	https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 1007-9327 (print) ISSN 2219-2840 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
October 1, 1995	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Weekly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Andrzej S Tarnawski	https://www.wjgnet.com/bpg/gerinfo/208
EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF	POLICY OF CO-AUTHORS
Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou- Bao Liu (Biliary Tract Disease)	https://www.wjgnet.com/bpg/GerInfo/310
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
http://www.wjgnet.com/1007-9327/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
March 7, 2024	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2024 Baishideng Publishing Group Inc	https://www.f6publishing.com
PUBLISHING PARTNER	PUBLISHING PARTNER'S OFFICIAL WEBSITE
Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University Biliary Tract Disease Institute, Fudan University	https://www.shca.org.cn https://www.zs-hospital.sh.cn
© 2024 Baishideng Publishing Group Inc. All rights reserved. 7(	)41 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

E-mail: office@baishideng.com https://www.wjgnet.com



WJG

# World Journal of Gastroenterology

Submit a Manuscript: https://www.f6publishing.com

World J Gastroenterol 2024 March 7; 30(9): 1108-1120

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

DOI: 10.3748/wjg.v30.i9.1108

ORIGINAL ARTICLE

## **Clinical Trials Study** Clinical manifestation, lifestyle, and treatment patterns of chronic erosive gastritis: A multicenter real-world study in China

Ying-Yun Yang, Ke-Min Li, Gui-Fang Xu, Cheng-Dang Wang, Hua Xiong, Xiao-Zhong Wang, Chun-Hui Wang, Bing-Yong Zhang, Hai-Xing Jiang, Jing Sun, Yan Xu, Li-Juan Zhang, Hao-Xuan Zheng, Xiang-Bin Xing, Liang-Jing Wang, Xiu-Li Zuo, Shi-Gang Ding, Rong Lin, Chun-Xiao Chen, Xing-Wei Wang, Jing-Nan Li

Ying-Yun Yang, Ke-Min Li, Department of Gastroenterology, Peking Union Medical College Specialty type: Gastroenterology Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing and hepatology 100730, China Provenance and peer review: Gui-Fang Xu, Department of Gastroenterology, Nanjing Drum Tower Hospital, Nanjing 21000, Unsolicited article; Externally peer Jiangsu Province, China reviewed. Cheng-Dang Wang, Department of Gastroenterology, The First Affiliated Hospital of Fujian Peer-review model: Single blind Medical University, Fuzhou 350005, Fujian Province, China Peer-review report's scientific Hua Xiong, Department of Gastroenterology, Renji Hospital, Shanghai 200127, China quality classification Grade A (Excellent): 0 Xiao-Zhong Wang, Department of Gastroenterology, Union Hospital of Fujian Medical Uni-Grade B (Very good): 0 versity, Fuzhou 350000, Fujian Province, China Grade C (Good): C Chun-Hui Wang, Department of Gastroenterology, West China Hospital of Sichuan University, Grade D (Fair): 0 Chengdu 610041, Sichuan Province, China Grade E (Poor): 0 Bing-Yong Zhang, Department of Gastroenterology and Hepatology, The People's Hospital of P-Reviewer: Massironi S, Italy Zhengzhou University, The Henan Provincial People's Hospital, Zhengzhou 450003, Henan Received: November 13, 2023 Province, China Peer-review started: November 13, Hai-Xing Jiang, Department of Gastroenterology, The First Affiliated Hospital of Guangxi 2023 Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China First decision: December 8, 2023 Revised: January 1, 2024 Jing Sun, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Accepted: February 2, 2024 Tong Univesrity, Ruijin Hospital, School Medicine, Shanghai 200025, China Article in press: February 2, 2024 Yan Xu, Department of Gastroenterology and Hepatology, China-Japan Union Hospital of Jilin Published online: March 7, 2024 University, Changchun 130033, Jilin Province, China Li-Juan Zhang, Department of Gastroenterology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China Hao-Xuan Zheng, Department of Gastroenterology, Nanfang Hospital, Guangzhou 510080, Guangdong Province, China

> Xiang-Bin Xing, Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China

Liang-Jing Wang, Department of Gastroenterology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China

Xiu-Li Zuo, Department of Gastroenterology, Shandong University Qilu Hospital, Jinan 250012, Shandong Province, China

Shi-Gang Ding, Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China

Rong Lin, Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China

Chun-Xiao Chen, Department of Gastroenterology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 315000, Zhejiang Province, China

Xing-Wei Wang, Department of Gastroenterology, Chongqing Daping Hospital, Chongqing 400042, China

Jing-Nan Li, Department of Gastroenterology, Peking Union Medical College Hospital, Beijing 100005, China

Jing-Nan Li, Key Laboratory of Gut Microbiota Translational Medicine Research, Chinese Academy of Medical Science, Beijing 100005, China

Corresponding author: Jing-Nan Li, MD, Chief Physician, Department of Gastroenterology, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100005, China. pumcjnl@126.com

#### Abstract

#### BACKGROUND

Although chronic erosive gastritis (CEG) is common, its clinical characteristics have not been fully elucidated. The lack of consensus regarding its treatment has resulted in varied treatment regimens.

#### AIM

To explore the clinical characteristics, treatment patterns, and short-term outcomes in CEG patients in China.

#### **METHODS**

We recruited patients with chronic non-atrophic or mild-to-moderate atrophic gastritis with erosion based on endoscopy and pathology. Patients and treating physicians completed a questionnaire regarding history, endoscopic findings, and treatment plans as well as a follow-up questionnaire to investigate changes in symptoms after 4 wk of treatment.

#### **RESULTS**

Three thousand five hundred sixty-three patients from 42 centers across 24 cities in China were included. Epigastric pain (68.0%), abdominal distension (62.6%), and postprandial fullness (47.5%) were the most common presenting symptoms. Gastritis was classified as chronic non-atrophic in 69.9% of patients. Among those with erosive lesions, 72.1% of patients had lesions in the antrum, 51.0% had multiple lesions, and 67.3% had superficial flat lesions. In patients with epigastric pain, the combination of a mucosal protective agent (MPA) and proton pump inhibitor was more effective. For those with postprandial fullness, acid regurgitation, early satiety, or nausea, a MPA appeared more promising.

#### **CONCLUSION**

CEG is a multifactorial disease which is common in Asian patients and has non-specific symptoms. Gastroscopy may play a major role in its detection and diagnosis. Treatment should be individualized based on symptom profile.

Key Words: Chronic erosive gastritis; Symptom; Endoscopic findings; Treatment pattern; Real-world

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.



**Core Tip:** This multicenter study is the first real-world observational study to explore lifestyle characteristics, symptoms, endoscopic findings, treatment patterns, and short-term outcomes in patients with chronic erosive gastritis in China. Our findings suggest that it is a multifactorial disease influenced by lifestyle, obesity, infection, emotion, and mood. Epigastric pain, abdominal distension, and postprandial fullness were the most common initial symptoms, which are non-specific. Therefore, gastroscopy may be valuable for detection and diagnosis. Individualized treatment based on symptom profile is crucial.

Citation: Yang YY, Li KM, Xu GF, Wang CD, Xiong H, Wang XZ, Wang CH, Zhang BY, Jiang HX, Sun J, Xu Y, Zhang LJ, Zheng HX, Xing XB, Wang LJ, Zuo XL, Ding SG, Lin R, Chen CX, Wang XW, Li JN. Clinical manifestation, lifestyle, and treatment patterns of chronic erosive gastritis: A multicenter real-world study in China. World J Gastroenterol 2024; 30(9): 1108-1120 URL: https://www.wjgnet.com/1007-9327/full/v30/i9/1108.htm DOI: https://dx.doi.org/10.3748/wjg.v30.i9.1108

#### INTRODUCTION

Chronic gastritis is a common illness that affects billions of individuals worldwide [1,2]. Among the different types, chronic erosive gastritis (CEG) is the most common. In 2014, the Chinese Chronic Gastritis Research group conducted a nationwide multicenter study that enrolled 8892 patients with chronic gastritis from 33 centers across 10 cities; 49.4% of patients were diagnosed with superficial gastritis and 42.3% with erosive gastritis, which indicated that chronic superficial gastritis and CEG are the most common endoscopic findings in Chinese patients[3]. Although CEG does not carry a risk of cancer, it causes histological changes in the gastric mucosa and various gastrointestinal (GI) symptoms that may result in decreased quality of life.

According to the Sydney System for the classification of gastritis, chronic gastritis can be divided into non-atrophic and atrophic types based on endoscopic and pathological evaluations<sup>[4]</sup>. The topographical patterns of chronic gastritis range from antrum-predominant to corpus-predominant gastritis or pangastritis<sup>[5]</sup>. Erosive gastritis is defined as any type of gastritis accompanied by erosions in the mucosa, which are identified as either flat or minimally depressed white spots surrounded by a reddish area that may be accompanied by superficial bleeding or small nodules with central umbilication that mimics octopus suckers<sup>[6]</sup>. In general, erosive gastritis involves inflammatory mucosal damage that can lead to ulceration or bleeding[7,8]. Although gastric carcinogenesis and peptic ulcers have attracted considerable research attention over the past decade, few studies have focused on CEG.

Whether the pathogenesis of erosive gastritis involves elevated production of gastric acid or is related to weakened mucosal defenses has been debated for decades [6,9]. Although Helicobacter pylori (H. pylori) infection [1,10], stress [11], and obesity[7] are potentially correlated with CEG incidence, further evidence is needed. Furthermore, the impact of medications such as non-steroidal anti-inflammatory drugs (NSAIDs) and warfarin on CEG remains unclear [12,13]. CEG risk factors, presentation, endoscopic and histopathological findings, therapeutic options, and treatment effects remain largely controversial. As a result, treatment practices vary. This study was conducted to aid in understanding the clinical and lifestyle characteristics, treatment patterns, and short-term outcomes of CEG in Chinese patients.

#### MATERIALS AND METHODS

#### Patient selection


This real-world, multicenter, prospective, observational cohort study was conducted in 42 participating centers in 24 cities in China from April 2019 to December 2019. The study flow chart is shown in Figure 1.

Patients aged 18 to 70 years with a diagnosis of chronic non-atrophic or mild-to-moderate atrophic gastritis with erosions based on both endoscopic and pathological evaluations were eligible for inclusion. We excluded patients with any of the following criteria: (1) Chronic atrophic gastritis with intraepithelial neoplasia; (2) other mucosal lesions, such as gastric ulcers; (3) diagnosis of dementia, delirium, severe mood disturbance, or other mental disorder; (4) diagnosis of severe cardiac or cerebrovascular disease; (5) malignancy that required ongoing treatment; (6) history of subtotal gastrectomy; (7) history of previous endoscopic procedure such as endoscopic submucosal dissection or endoscopic mucosal resection; (8) pregnancy; or (9) any other condition that was considered unsuitable for the study. Erosive gastritis was determined by endoscopy according to the Sydney System and 2017 Chinese consensus on chronic gastritis[14]. All patients provided written informed consent. The study protocol was approved by the ethics committees of all participating institutions (Clinical registration number: ChiCTR2100047690).

#### Study design

Patients were asked to complete the first part of a baseline questionnaire, which contained questions regarding lifestyle, other medical conditions, medications, and major GI symptoms and their severity, with the help of physicians. Each symptom was graded as 0 (non-existent), 1 (mild and occasional), 2 (obvious and frequent, partially disturbing daily life), or 3 (severe, disturbing daily life). Physicians then independently completed the second part of the questionnaire, which





#### Figure 1 Study flow chart.

contained information regarding endoscopy findings and treatment. Four weeks later, patients completed a follow-up questionnaire, which contained questions regarding medication compliance and major GI symptoms and their severity with the help of medical assistants, either in the clinic or by telephone interview.

#### Clinical effect evaluation

The severity of symptoms was scored at the time of enrollment and during follow-up. Symptoms included epigastric pain, abdominal distension, postprandial fullness, early satiety, acid regurgitation, nausea, belching, vomiting, and others. Clinical effectiveness of treatment was defined as a decrease in symptom score. Participants were categorized into four groups according to treatment strategy: Mucosal protective agent (MPA), proton pump inhibitor (PPI), MPA + PPI, and MPA + PPI + prokinetic drug (PD).

#### Statistical analysis

Categorical variables are presented as absolute values with relative frequencies. Comparisons of categorical variables were performed using the chi-square test or Fisher's exact test as appropriate. Odds ratios (ORs) with 95% confidence intervals (95%CIs) were calculated using logistic regression and adjusted for age and sex. Statistical analyses were performed using SAS software version 9.3 (SAS Institute Inc., Cary, NC, United States). All tests were two-sided. P < 0.05 was considered significant.

#### RESULTS

#### Physician characteristics

A total of 111 physicians were randomly selected from a panel of gastroenterologists from the participating centers. Sixtyone (55.0%) were men and fifty (45.0%) were women. The demographic distribution of each participating center is shown in Supplementary Figure 1.

#### Patient characteristics

The data of 3563 patients were included for analysis. Patient demographics are shown in Supplementary Figure 1. Patients aged between 40 and 60 years comprised 52.7% of the patients and 49.5% were men. Few patients reported comorbidities, although 310 (8.7%) had a family history of malignancy (Table 1).

#### Lifestyle

Two-thirds of patients (66.2%) had no history of smoking; 29.4% and 4.4% were current or former smokers, respectively. Half (50.1%) had no history of alcohol consumption, whereas 45.3% and 4.6% were current or former drinkers, respectively. Regarding dietary habits, 66% of patients ate a regular diet and 69.8% never drank coffee. Detailed dietary preferences are shown in Table 1. Almost half of patients (47.1%) slept  $\geq$  7 h per night on average and 32.8% reported irregular sleep (Table 1).

#### Medication

NSAIDs were the most commonly used medication (8.3%). Anticoagulation drugs and corticosteroids were used by 4.6% and 2.0% of patients, respectively (Table 1).



Age group at enrollment (ry)Q20S0 (D5)Q30 (Q3)Q3 (Q3)Q30 (Q3)Q3 (Q3)ConcorditionQ3 (Q3)Unred close or cirbosisQ3 (Q3)Choric close or cirbosisQ3 (Q3)Unred close or cirbosisQ3 (Q3)Choric close or cirbosis	Table 1 Patient characteristics, n (%)	
Ageogeneration12.9a[3.19]12.9a[3.10]13.4a[3.10]13.4a[3.10]13.4a[3.10]14.9a[3.10]14.9a[3.10]24.0a[3.10]25.0a[3.10]26.0a[3.10]27.0a[3.10]28.0a[3.10]29.0a[3.10]20.0a[3.10] </td <td>Variable</td> <td>n = 3563</td>	Variable	n = 3563
<table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-row><table-row><table-row></table-row><table-row><table-row><table-container></table-container></table-row><table-row><table-row></table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row><table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>	I Baseline characteristics	
<table-row><table-container><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></table-container></table-row>	Age group at enrollment (yr)	
FailArrow45-020(23)5-6030(0,0)5-6030(0,0)5-6030(0,0)Conder105 (0,0)Main105 (0,0)Fende109 (0,0)Conorbiditis310 (0,0)	0-20	53 (1.5)
AlgoAug51-00990,630500900,630Conder900,630Conder1000,600 <t< td=""><td>21-30</td><td>321 (9.0)</td></t<>	21-30	321 (9.0)
shaleBender>60(30)Conder(30)Fende(30)Concoldition(30)Bilerdux(30)Bilerdux(30)Concoldition(30)Liver disease or circhesis(30)Panconic disease(30)Charlendus <td< td=""><td>31-40</td><td>617 (17.3)</td></td<>	31-40	617 (17.3)
<table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row>	41-50	920 (25.8)
General     765 (495)       Male     765 (495)       Fenale     785 (55)       Conorbidities     816 (5)       Even disces or cirrhosis     81 (30)       Concristidisea     81 (30)       Concristidisea     30 (34)       Concristidisea     81 (30)       Concristidisea     81 (30)       Concristidisea     81 (30)       Concristidisea     81 (30)       Concristiding disease     10 (37)       Concristiding disease     10 (30)       Concristiding disease     10 (30)       Concristiding disease     10 (30)       Concrestiding disease     <	51-60	959 (26.9)
<table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>	> 60	693 (19.4)
FeadePart of the second se	Gender	
CompditiesBiterfux\$40,6)Liver disease or cirrhosis\$20,6)Panceatic disease\$20,6)Autommune disease\$20,6)Conci kidong disease\$20,6)	Male	1765 (49.5)
<table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>	Female	1798 (50.5)
Ler disease cirthosis9Derceatic disease86.16)Autoinmue disease10.04)Chonic kidney disease20.15)Post Glaugery010.87)Family history of malignancy108.67)Gastric carcinoma105.52)Other malignancy125.53)Choir kidney disease126.10)Post Glaugery126.10)Choir kidney disease126.10)Choir kidney disease126.10)Choir kidney disease126.10)Choir kidney disease126.10)Choir kidney disease126.10)Post Glaugery126.10)Post Glaugery126.10)Choir kidney disease126.20)Post Glaugery126.20)Post Glaugery126.20)Post Glaugery127.62)Post Glaugery127.62)Post Glaugery126.62)Post Glaugery <td>Comorbidities</td> <td></td>	Comorbidities	
Antominume disease     3 (04)       Chronic kidnay disease     3 (04)       Chronic kidnay disease     6 (1.7)       Post Cli surgery     6 (0.7)       Family history of malignancy     30 (8.7)       Castric carcinoma     10 (8.7)       Coher malignancy     12 (3.5)       Other malignancy     12 (3.5)       Other malignancy     12 (3.5)       Chronic kinkstry     12 (3.5)       Never     13 (04)       Former user     163 (4.6)       Les than 1 dper week     95 (26.8)       12 dper week     28 (8.1)       3-6 dper week     20 (6.3)       every day     16 (3.6)       Stroking history     237 (62.2)       Former smoker     237 (62.2)       Former smoker     29 (64.2)       Les than 1 pack per week     29 (64.2)       Stroking history     27 (7.8)       Stroking history     27 (7.8)       Stroker per week     36 (6.6)       Les than 1 pack per week     20 (6.6)       Stroker per week     37 (6.2)       Stroker per week     36	Bile reflux	343 (9.6)
<table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-container><table-container><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>	Liver disease or cirrhosis	137 (3.8)
And     25       Pot Gi surgery     61 (.7)       Fanily history of malignancy     30 (8.7)       Gastric carcinoma     185 (5.2)       Other malignancy     125 (3.5)       Other malignancy     125 (3.5)       Il lifestyle	Pancreatic disease	58 (1.6)
PedG Surgery61 (7)Family history of malignancy30 (8.7)Gastric accinoma185 (5.2)Other malignancy152 (3.5)I Lifsstyle	Autoimmune disease	13 (0.4)
Analy history of malignancy30 (0 8.7)Gastric carcinoma185 (5.2)Other malignancy120 (3.5)Other malignancy120 (3.5)Il Lifestyle174 (5.1)Never164 (6.1)Former user163 (6.2)Las than 1 der week285 (8.1)3-6 der week286 (8.1)3-6 der week206 (5.8)everyday164 (5.2)Never205 (6.2)Never205 (6.2)Never205 (6.2)Never205 (6.2)Stant 1 der week205 (6.2)Stant 1 der we	Chronic kidney disease	52 (1.5)
Gasric archoma     185 (2)       Other malignancy     125 (3)       II Lifestyle     25 (3)       Atcholuse history     784 (50.1)       Never     784 (50.1)       Former user     163 (4)       Las than 1 d per week     55 (28.8)       1-2 d per week     26 (8)       3-6 d per week     206 (58.2)       everyday     167 (47.2)       Never     167 (47.2)       Never     295 (66.2)       Former smoker     170 (49.2)       Former smoker     296 (69.2)       1-2 pack per week     296 (69.2)       1-2 packs per week     206 (69.2)	Post GI surgery	61 (1.7)
Oher malignancy125 (3.5)Oher malignancy	Family history of malignancy	310 (8.7)
I LifestyleAlcohol use historyNever784 (50,100000000000000000000000000000000000	Gastric carcinoma	185 (5.2)
Akohol use history     Never   174 (50.1)     Former user   163 (4.6)     Less than 1 dper week   955 (26.8)     1-2 dper week   288 (8.1)     3-6 dper week   286 (8.1)     every day   06 (5.8)     synchrony   171 (7.8)     Never   237 (66.2)     Never   290 (6.4)     1-2 packs per week   200 (7.8)     1-2	Other malignancy	125 (3.5)
Never184 (0.1)Former user163 (0.1)Les than 1 dper wels95 (26.8)1-2 d per wels28 (8.1)3-6 d per wels26 (5.8)everyday16 (3.7)Sorking history21 (3.7)Never257 (66.2)Former smoker157 (4.3)1-2 packs per wels29 (6.4)3-6 packs per wels20 (6.6)3-6 packs per wels20 (6.6)Moret and 1 pack per de data37 (7.8)3-6 packs per wels30 (8.6)Moret and 1 pack per de data30 (8.6)Moret and 1 pack per de data31 (3.6)Moret and 1 pack per de data21 (3.6)Moret and 1 pack per de data31 (3.6)Moret and 2 pack per de data31 (3.6)Moret	II Lifestyle	
Former user     163 (4.6)       Former user     163 (4.6)       Les than 1 dper week     95 (26.8)       1-2 d per week     288 (8.1)       3-6 d per week     206 (5.8)       everyday     26 (7.9)       everyday     167 (4.7)       Stroking history     257 (66.2)       Former smoker     29 (64.2)       Les than 1 pack per week     29 (6.4)       3-6 packs per week     207 (7.8)       3-6 packs per week     207 (7.8)       3-6 packs per week     206 (6.6)       More than 1 pack per day     207 (7.8)       D ter regularity     252 (6.0)       Regular     235 (26.0)	Alcohol use history	
Les than 1 d per week   955 (26.8)     1-2 d per week   288 (8.1)     3-6 d per week   206 (5.8)     everyday   167 (4.7)     Stroking history   357 (66.2)     Never   205 (6.9)     Former smoker   297 (7.8)     1-2 packs per week   207 (7.8)     3-6 packs per week   206 (6.9)     3-7 pack per week   206 (6.9)     3-6 packs per week   206 (6.9)     3-7 pack per week	Never	1784 (50.1)
1-2 d per week288 (8.1)3-6 d per week26 (5.8)everyday167 (4.7)smoking history257 (66.2)Never257 (66.2)Former smoker157 (4.4)1-2 packs per week229 (6.4)1-2 packs per week237 (7.8)3-6 packs per week236 (6.6)More than 1 pack per day30 (8.6)Diet regularity12Regular252 (66.0)Standard per week252 (60.0)Standard per week252 (60.0)More than 1 pack per day252 (60.0)Diet regularity125 (26.0)Standard per week252 (60.0)Standard per week	Former user	163 (4.6)
3-6 d per week206 (5.8)everyday167 (4.7)everyday167 (4.7)Snoking history257 (6.6)Former smoker157 (4.4)Former smoker29 (6.4)1-2 packs per week26 (6.6)3-6 packs per week307 (8.6)More than 1 pack per day307 (8.6)Dier regularity252 (6.6)Regular352 (6.6)Regular in 1-2 d per week352 (6.6)Regular in 1-2 d per week352 (6.6)	Less than 1 d per week	955 (26.8)
everyday 2012 Snoking history 2012 Never 2015 Former smoker 2015 Former smoker 2016 Less than 1 pack per week 2016 3-6 packs per week 2017 Alore than 1 pack per day 2016 More than 1 pack per day 2016 More than 1 pack per day 2017 Segular 1.2 pack 2017 More than 1 pack per day	1-2 d per week	288 (8.1)
Snoking historyNever357 (6.2)Former smoker157 (4.4)Less than 1 pack per week229 (6.4)3-6 packs per week277 (7.8)More than 1 pack per day36 (6.6)Diet regularity378 (8.6)Regular252 (6.60)In 2 pack per week252 (6.00)	3-6 d per week	206 (5.8)
Never2357 (66.2)Former smoker157 (4.4)Less than 1 pack per week229 (6.4)1-2 packs per week277 (7.8)3-6 packs per week236 (6.6)More than 1 pack per day307 (8.6)Diet regularity352 (66.0)Regular2352 (66.0)I regular in 1-2 d per week617 (17.3)	everyday	167 (4.7)
Former smoker157 (4.4)Less than 1 pack per week229 (6.4)1-2 packs per week277 (7.8)3-6 packs per week236 (6.6)More than 1 pack per day307 (8.6)Diet regularity352 (66.0)Regular352 (66.0)I regular in 1-2 d per week617 (7.3)	Smoking history	
Less than 1 pack per week   229 (6.4)     1-2 packs per week   277 (7.8)     3-6 packs per week   236 (6.6)     More than 1 pack per day   307 (8.6)     Diet regularity   2352 (66.0)     Regular   2352 (66.0)     I regular in 1-2 d per week   617 (17.3)	Never	2357 (66.2)
1-2 packs per week   277 (7.8)     3-6 packs per week   236 (6.6)     More than 1 pack per day   307 (8.6)     Diet regularity   235 (66.0)     Regular   2352 (66.0)     Irregular in 1-2 d per week   617 (7.3)	Former smoker	157 (4.4)
3-6 packs per week   236 (6.6)     More than 1 pack per day   307 (8.6)     Diet regularity   325 (66.0)     Regular in 1-2 d per week   617 (7.3)	Less than 1 pack per week	229 (6.4)
More than 1 pack per day307 (8.6)Diet regularity2352 (66.0)Regular in 1-2 d per week617 (17.3)	1-2 packs per week	277 (7.8)
Diet regularity   Regular   1regular in 1-2 d per week   617 (17.3)	3-6 packs per week	236 (6.6)
Regular     2352 (66.0)       Irregular in 1-2 d per week     617 (17.3)	More than 1 pack per day	307 (8.6)
Irregular in 1-2 d per week 617 (17.3)	Diet regularity	
	Regular	2352 (66.0)
Irregular in 3.6 d per week	Irregular in 1-2 d per week	617 (17.3)
200 (0.0)	Irregular in 3-6 d per week	285 (8.0)
Irregular everyday 309 (8.7)	Irregular everyday	309 (8.7)

Baisbideng® WJG | https://www.wjgnet.com

Coffee intake	
Never	2486 (69.8)
Less than 1 d per week	633 (17.8)
1-2 d per week	178 (5.0)
3-6 d per week	130 (3.6)
Everyday	136 (3.8)
Diet preference (multiple choices)	
Normal	1477 (41.5)
Healthy diet (vegetable dominate)	904 (25.4)
Spicy food	841 (23.6)
Smoked or pickled food	527 (14.8)
Hot food	386 (10.8)
Sleep duration	
$\geq$ 7 h per day on average	1680 (47.1)
< 7 h per day on average	1883 (52.8)
Sleep regularity	
Regular	2391 (67.1)
Irregular	1172 (32.8)
III Medication	
NSAIDs	295 (8.3)
Anticoagulation drugs	164 (4.6)
Corticosteroids	73 (2.0)
IV Stress and mood	
Feeling stressed	974 (27.3)
Major life events	386 (10.8)
Feeling depressed	865 (24.3)
Feeling anxious	1138 (31.9)

GI: Gastrointestinal; NSAIDs: Non-steroidal anti-inflammatory drugs.

#### Stress and mood

A relatively high proportion of patients reported stress or mood issues: 27.3% of patients felt stressed, 10.8% of patients underwent major life events in the previous 6 months, 24.3% of patients felt depressed, and 31.9% suffered from anxiety (Table 1).

#### H. pylori infection

Among the 2922 patients who underwent *H. pylori* testing, 24.8% were positive (Table 1).

#### Initial symptoms and endoscopic findings

Data regarding initial symptoms and endoscopic findings were collected through history taking and gastroscopic reports. Eight major symptoms and their severity were evaluated. Symptom duration varied: 26.7% of patients had symptoms for less than 3 months and 34.7% had symptoms for more than 1 year (Figure 2A). The most common symptoms were epigastric pain, abdominal distension, and postprandial fullness. Symptoms and their severity were similar between nonatrophic gastritis patients and all patients (Figure 2, Supplementary Figure 2, Supplementary Tables 1 and 2). Among patients with erosions, 72.0% were diagnosed with chronic non-atrophic gastritis, 22.5% with chronic mild atrophic gastritis, and 5.5% with chronic moderate atrophic gastritis. Most patients had erosions in the gastric antrum. Slightly more than half (51.0%) had a single lesion and 67.3% had superficial flat lesions (Table 2).

#### Treatment patterns and efficacy

Treatment patterns are shown in Table 3. Lifestyle instructions without medication were prescribed in 10.3% of patients;



Baishidena® WJG | https://www.wjgnet.com

Table 2 Endoscopic findings, n (%)					
Variable	n = 3563				
Gastritis classification					
Chronic non-atrophy gastritis	2489 (69.9)				
Chronic mild-atrophy gastritis	819 (23.0)				
Chronic moderate-atrophy gastritis	255 (7.1)				
Topographical pattern of erosion					
Fundus involvement	498 (14.0)				
Corpus involvement	642 (18.0)				
Antrum involvement	2568 (72.1)				
Angle involvement	154 (4.3)				
Location involvement					
Single	3292 (92.4)				
Multiple	271 (7.6)				
Erosive lesion number					
Single lesion	1747 (49.0)				
Multiple lesions	1816 (51.0)				
Erosive lesion morphology					
Superficial flat	2399 (67.3)				
Protrude nodules	1164 (32.7)				

Table 3 Treatment patterns of chronic erosive gastritis, n (%)						
Variable	n = 3563	Variable	n = 3563			
Treatment patterns						
Only lifestyle instructions	368 (10.3)					
Drug combinations		Drug by category				
MPA + PPI	1126 (31.6)	MPA	2380 (66.8)			
MPA	392 (11.0)	PPI	2489 (69.9)			
PPI	325 (9.1)	Anti-Hp	404 (11.3)			
MPA + PPI + PD	302 (8.5)	H <sub>2</sub> RA	23 (0.6)			
PPI + anti-Hp	161 (4.5)	PD	608 (17.1)			
MPA + PPI + anti-Hp	151 (4.2)	TCM	250 (7.0)			
MPA + PD	92 (2.6)	Others	260 (7.3)			
MPA + PPI + TCM	65 (1.8)					
PPI + PD	51 (1.4)					
PPI + TCM	42 (1.2)					
Others	488 (13.7)					

MPA: Mucosal protective agent; PPI: Proton pump inhibitor; PD: Prokinetic drug; Hp: *Helicobacter pylori*; TCM: Traditional Chinese medicine; H<sub>2</sub>RA: Histamine-2 receptor antagonist.

Baisbideng® WJG | https://www.wjgnet.com




Figure 2 Initial symptoms and their severity. A: Symptom duration for all patients; B: Distribution of initial symptoms in all patients with gastritis; C: Distribution of symptoms innon-atrophic gastritis patients; D: Distribution of symptoms in atrophic gastritis patients.

89% received a drug or drug combination. The most frequently used regimens were MPA + PPI (35.24%), MPA (12.27%), PPI (10.17%), and MPA + PPI + PD (9.45%). The effectiveness of these four treatment regimens against each symptom is shown in Table 4. Table 5 shows the same with patients stratified according to H. pylori status. Treatment effectiveness was generally lower in *H. pylori*-positive patients. Effectiveness was higher in the MPA group than the PPI group for postprandial fullness (48.7% vs 32.6%), early satiety (36.7% vs 18.2%), nausea (34.4% vs 18.8%), and epigastric pain (55.9% vs 47.7%). Effectiveness was higher in the PPI + MPA group than the PPI group for epigastric pain (66.7% vs 47.7%) and acid regurgitation (41.4% vs 31.4%). For abdominal distension and belching, effectiveness was highest in the PPI + MPA + PD group. Comparisons between groups after adjusting for sex and age are shown in Table 6.

#### DISCUSSION

Previous studies have suggested that erosions are common in chronic gastritis, especially Asian patients. In a multicenter chronic gastritis survey, 42.3% of patients were found to have CEG of varying severity[3]. Another multicenter study conducted in France that enrolled 3287 patients with upper GI bleeding revealed that 11.8% of patients aged < 75 years and 13.9% of patients aged > 75 years had gastroduodenal erosions[8]. However, there is currently insufficient data and evidence regarding CEG risk factors, symptoms, endoscopic and pathologic characteristics, and treatment strategies [15]. As a result, treatment patterns vary extensively. Moreover, evidence regarding CEG treatment outcomes is limited, especially regarding symptom improvement. Therefore, we conducted this study, which is the first real-world observational and non-interventional study in China to explore lifestyle characteristics, symptoms, endoscopic findings, treatment patterns, and short-term outcomes in patients with CEG.

In regard to patient characteristics, CEG did not show a sex predominance. Furthermore, contrary to our expectations, more than half of the patients with erosions had no history of alcohol consumption or smoking, and more than 60.0% ate a regular diet and had normal or healthy diet preferences. However, a considerable proportion of patients exhibited mood problems. Specifically, 27.3% of patients felt stressed, 24.3% felt depressed, and 31.9% felt anxious, which suggested that mood disturbances may play a role in the development of erosions. Treatment of stress-induced gastritis and gastric ulcers in the intensive care unit setting has been discussed previously<sup>[11]</sup>; however, the relationship between daily life stress and CEG has not been fully ascertained. Our results and those of previous studies suggest that CEG is a

Zaishidena® WJG https://www.wjgnet.com

#### Yang YY et al. A real-world study of CEG

Table 4 Effectiveness of the four most frequently used treatment regimens against the various symptoms, <i>n</i> (%)								
	MPA effectiveness, <i>n</i> = 3563	PPI effectiveness, <i>n</i> = 3563	MPA + PPI effectiveness, <i>n</i> = 3563	MPA + PPI + PD effectiveness, <i>n</i> = 3563	P value			
Epigastric pain	219 (55.9)	155 (47.7)	751 (66.7)	207 (68.5)	< 0.001			
Abdominal distension	212 (54.1)	158 (48.6)	608 (54.0)	194 (64.2)	0.001			
Postprandial fullness	191 (48.7)	106 (32.6)	455 (40.4)	156 (51.7)	< 0.001			
Early satiety	144 (36.7)	59 (18.2)	309 (27.4)	103 (34.1)	< 0.001			
Acid regurgitation	159 (40.6)	102 (31.4)	466 (41.4)	164 (54.3)	< 0.001			
Nausea	135 (34.4)	61 (18.8)	261 (23.2)	86 (28.5)	< 0.001			
Belch	168 (42.9)	88 (27.1)	355 (31.5)	152 (50.3)	< 0.001			
Vomiting	87 (22.2)	38 (11.7)	140 (12.4)	43 (14.2)	< 0.001			
Others	72 (18.4)	14 (4.3)	42 (3.7)	21 (7.0)	< 0.001			

MPA: Mucosal protective agent; PPI: Proton pump inhibitor; PD: Prokinetic drug.

#### Table 5 Treatment effectiveness with patients stratified according to Helicobacter pylori status, n (%)

	MPA effectiveness, <i>n</i> = 3563		PPI effectiveness, <i>n</i> = 3563		MPA + PPI effectiveness, <i>n</i> = 3563		MPA + PPI + PD effectiveness, <i>n</i> = 3563		P
	Hp (+)	Нр (-)	Нр (+)	Нр (-)	Hp (+)	Нр (-)	Нр (+)	Нр (-)	- value
Epigastric pain	26 (47.3)	148 (56.5)	27 (51.9)	86 (42.8)	91 (67.9)	527 (66.5)	10 (47.6)	161 (70.3)	0
Abdominal distension	24 (43.6)	143 (54.6)	29 (55.8)	99 (49.3)	74 (55.2)	424 (53.5)	15 (71.4)	141 (61.6)	0.092
Postprandial fullness	21 (38.2)	135 (51.5)	22 (42.3)	63 (31.3)	55 (41.0)	323 (40.7)	8 (38.1)	118 (51.5)	0
Early satiety	19 (34.5)	102 (38.9)	15 (28.8)	31 (15.4)	36 (26.9)	230 (29.0)	6 (28.6)	83 (36.2)	0
Acid regurgitation	29 (52.7)	102 (38.9)	25 (48.1)	61 (30.3)	38 (28.4)	340 (42.9)	10 (47.6)	127 (55.5)	0
Nausea	24 (43.6)	88 (33.6)	15 (28.8)	36 (17.9)	28 (20.9)	190 (24.0)	2 (9.5)	73 (31.9)	0
Belch	28 (50.9)	115 (43.9)	21 (40.4)	50 (24.9)	37 (27.6)	259 (32.7)	4 (19.0)	118 (51.5)	0
Vomiting	16 (29.1)	54 (20.6)	11 (21.2)	18 (9.0)	17 (12.7)	103 (13.0)	1 (4.8)	38 (16.6)	0
Others	21 (38.2)	135 (51.5)	22 (42.3)	63 (31.3)	55 (41.0)	323 (40.7)	8 (38.1)	118 (51.5)	0

MPA: Mucosal protective agent; PPI: Proton pump inhibitor; PD: Prokinetic drug; Hp: Helicobacter pylori.

multifactorial disease which is influenced by lifestyle, obesity, infection, emotion, and mood. The correlation between a single factor, such as dietary habits, and disease incidence remains unclear and further studies are warranted.

The FUTURE study revealed that among patients with chronic symptomatic gastritis, 48.2% experienced heartburn, 68.0% had epigastralgia, and 67.5% had epigastric fullness. These were the most common symptoms[16]. In our study, the most common symptom was epigastric pain (68.0%), followed by abdominal distension (62.6%), postprandial fullness (47.5%), acid regurgitation (43.4%), belching (39.6%), early satiety (30.5%), nausea (26.7%), and vomiting (13.9%); most of these were mild or moderate in severity. To further clarify the symptom profile of erosive gastritis, we compared the ratios of different symptoms in all patients, which were comparable between those with chronic non-atrophic gastritis and those with chronic atrophic gastritis. Epigastralgia, epigastric burning, postprandial epigastric fullness, and early satiation are typical symptoms of functional dyspepsia[17]. The symptoms of CEG are non-specific and similar to those of dyspepsia. Differentiating these two diseases is crucial. A recent meta-analysis indicated that the prevalence of functional dyspepsia is higher in Western countries than in Asian countries[18]. Moreover, questions have been raised regarding the inconsistent symptom clusters for functional GI disorders in China[19]. Thus, we speculate that the lack of consensus poses difficulties in identifying CEG, which may contribute to the disparate prevalence between Asian and Western countries. Previous studies have demonstrated that the prevalence of CEG is not considered low in China and other Asian countries, which suggests that gastroscopy for patients with the above symptoms may help physicians detect and diagnose CEG in Asian patients.

Baishidena® WJG https://www.wjgnet.com

Table 6 Treatment response comparisons (n = 3563)							
	PPI vs MPA		PPI vs MPA + PPI		PPI vs MPA + PPI	PPI vs MPA + PPI + PD	
	OR (95%WCL)	P value	OR (95%WCL)	P value	OR (95%WCL)	P value	
Epigastric pain	0.73 (0.54-0.98)	0.039	0.46 (0.36-0.59)	< 0.001	0.42 (0.30-0.58)	< 0.001	
Abdominal distension	0.81 (0.60-1.09)	0.162	0.81 (0.63-1.04)	0.091	0.53 (0.38-0.73)	< 0.001	
Postprandial fullness	0.51 (0.38-0.69)	< 0.001	0.71 (0.55-0.93)	0.011	0.45 (0.33-0.62)	< 0.001	
Early satiety	0.38 (0.27-0.54)	< 0.001	0.59 (0.43-0.80)	< 0.001	0.42 (0.29-0.61)	< 0.001	
Acid regurgitation	0.68 (0.50-0.93)	0.016	0.65 (0.50-0.85)	0.001	0.38 (0.28-0.53)	< 0.001	
Nausea	0.44 (0.31-0.63)	< 0.001	0.77 (0.57-1.06)	0.106	0.57 (0.39-0.83)	0.004	
Belch	0.50 (0.37-0.69)	< 0.001	0.81 (0.61-1.07)	0.133	0.36 (0.26-0.51)	< 0.001	
Vomiting	0.47 (0.31-0.71)	< 0.001	0.94 (0.64-1.37)	0.730	0.79 (0.49-1.26)	0.322	
Others	0.21 (0.11-0.37)	< 0.001	1.19 (0.64-2.22)	0.578	0.61 (0.31-1.23)	0.168	

MPA: Mucosal protective agent; PPI: Proton pump inhibitor; PD: Prokinetic drug; WCL: Weighted case load.

Current mainstream treatment options for CEG include lifestyle guidance, MPAs, PPIs, and other symptomatic treatments. Several studies have demonstrated that geranylgeranyl acetone treatment is more effective than cimetidine for chronic gastritis-associated erosions and petechial hemorrhage[20]. In addition, rebamipide had a stronger suppressing effect on mucosal inflammation and provided greater symptom relief in CEG patients than sucralfate[10]. Furthermore, famotidine is effective in relieving abdominal symptoms in chronic symptomatic gastritis[16]. For H. pyloriassociated gastritis, anti-H. pylori therapy is recommended and accepted by physicians [21,22]. However, a significant number of patients in our study were not treated using anti-H. pylori regimens and H. pylori-positive patients consistently exhibited lower symptom relief rates. Treatment of CEG varies across different centers[10,23], which is partially because of a lack of consensus and lack of treatment guidelines. However, high-level evidence evaluating the efficacy of existing treatment regimens is currently limited. In our study, PPIs and MPAs were used by 69.9% and 66.8% of patients, respectively, and 31.6% received combination treatment. Further studies comparing relief of the various symptoms between PPI, MPA, PPI + MPA, and PPI + MPA + PD may provide valuable information for selecting the most appropriate drug regimen. If epigastric pain is the predominant symptom, a MPA + PPI may provide a better response than a PPI or MPA alone. If abdominal distension is the predominant symptom, MPA may provide a slightly superior response than PPI; however, combining the two did not offer an additional benefit. Nonetheless, adding a PD to a combination of an MPA and a PPI seemed to provide greater symptom relief. If postprandial fullness, early satiety, or nausea are the most notable symptoms, the use of an MPA may be the optimal choice. When symptoms are predominantly related to acid reflux, a PPI or PPI + MPA are more effective. For patients whose predominant complaint is dyspepsia, treatment with an MPA is recommended; adding a PD may provide a better response in some cases. Our results demonstrate that individualized treatment based on symptom profile is crucial for patients with CEG.

This study is subject to several limitations. First, the absence of a control group comprising healthy individuals limits our capacity to robustly identify risk factors. Second, follow-up was only a month. While this timeframe is adequate for preliminary assessment of therapeutic responses, it is inadequate to provide a comprehensive understanding of long-term disease progression or sustainability of treatment effects. It is imperative for future studies to incorporate longer follow-up periods to thoroughly evaluate the long-term impact of treatment on symptoms, endoscopic findings, and histopathological changes and identify any late-onset adverse effects or diminished effectiveness.

#### CONCLUSION

We conducted the first multicenter real-world study to assess clinical characteristics, treatment patterns, and short-term outcomes in patients with CEG in China. The development of CEG is likely a multifactorial process. Epigastric pain, abdominal distension, and postprandial fullness were the most common initial symptoms. CEG is relatively common in Asians and clinical symptoms are non-specific. Therefore, gastroscopy may be valuable for CEG detection and diagnosis. Our comparisons of symptom relief between different treatment strategies should provide useful information to fellow clinicians regarding treatment selection. Patients with acid reflux symptoms may respond best to a PPI or PPI + MPA, whereas an MPA may be more effective for those with dyspepsia; in some cases, combination therapy with a PD may also be effective. Patients testing positive for *H. pylori* experience better symptom relief when anti-H pylori therapy is used. Taken together, our study highlights the need to individualize CEG treatment based on symptom profile.

Zaishidena® WJG https://www.wjgnet.com

#### **ARTICLE HIGHLIGHTS**

#### Research background

This multicenter observational study delves into chronic erosive gastritis (CEG) in China, a condition whose clinical characteristics and treatment approaches have been inadequately explored. It illuminates the commonality of CEG and its varied clinical presentations, emphasizing the necessity of a better understanding of its treatment patterns and short-term outcomes

#### Research motivation

Addressing the pressing need for clarity in the clinical management of CEG, the study seeks to demystify the disease's symptomatology, lifestyle influences, endoscopic findings, and treatment efficacies. It aspires to enhance the understanding of CEG's multifactorial nature and guide more effective, personalized treatment strategies.

#### Research objectives

To explore the clinical characteristics, treatment patterns, and short-term outcomes in CEG patients in China.

#### Research methods

Employing a prospective observational cohort approach, the study involved patients with chronic non-atrophic or mildto-moderate atrophic gastritis with erosions. It combined questionnaires, endoscopic and pathological evaluations, and follow-up assessments to evaluate treatment responses and lifestyle characteristics, offering a comprehensive view of CEG's clinical landscape.

#### Research results

The study reveals the predominance of symptoms like epigastric pain, abdominal distension, and postprandial fullness in CEG, with treatments like mucosal protective agents and proton pump inhibitors showing varying effectiveness. It underscores the non-specific nature of CEG symptoms and the importance of gastroscopy in diagnosis, especially in Asian populations.

#### Research conclusions

This investigation proposes new insights into CEG, highlighting its multifactorial etiology influenced by lifestyle, obesity, infection, and emotional factors. The study's findings advocate for individualized treatment strategies based on specific symptom profiles, enhancing treatment efficacy.

#### Research perspectives

Future research should focus on long-term outcomes of CEG treatments, the sustainability of therapeutic effects, and the identification of potential late-onset side effects. Extending the understanding of CEG's long-term progression and refining treatment approaches are crucial steps forward.

#### FOOTNOTES

Author contributions: Li JN, Yang YY, Xu GF, Wang CD, Wang XZ, Wang CH, Zhang BY, and Jiang HX contributed to the conception and design of the study; Yang YY, Xu GF, Wang CD, Xiong H, Wang XZ, Wang CH, Zhang BY, Jiang HX, Sun J, Xu Y, Yang YY, Xu GF, Wang CD, Xiong H, Wang XZ, Wang CH, Zhang BY, Jiang HX, Sun J, Xu Y, Zhang LJ, Zheng HX, Xing XB, Wang LJ, Zuo XL, Ding SG, Lin R, Chen CX, Wang XW, and Li JN performed the data collection; Yang YY, Li KM, Li JN, Xu Y, Wang LJ, Ding SG, and Lin R performed the data analysis and interpretation; Yang YY, Li KM, and Li JN performed the statistical analysis; Yang YY and Li KM wrote the first draft of the manuscript; Wang CD, Xiong H, Wang XZ, Wang CH, Zhang BY, Jiang HX, Sun J, Xu Y, Wang LJ, Ding SG, and Lin R revised the manuscript; Li JN and Yang YY contributed to funding acquisition; and all authors read and approved the final manuscript.

Supported by the National Key Clinical Specialty Construction Project, No. ZK108000; and CAMS Innovation Fund for Medical Sciences, No. 2021-I2M-C&T-A-001 and No. 2022-I2M-C&T-B-012.

Institutional review board statement: The study is reviewed and approved by the Local Ethics Committees of Peking union medical college hospital (Approval No. S-K700).

Clinical trial registration statement: This study is registered at Chinese Clinical Trial Registry (ChiCTR). The registration identification number is ChiCTR2100047690.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** There are no conflicts of interest to report.

Data sharing statement: No additional data are available.



CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

#### Country/Territory of origin: China

**ORCID number:** Ying-Yun Yang 0000-0002-2373-685X; Cheng-Dang Wang 0000-0003-0855-9055; Xiao-Zhong Wang 0000-0003-1756-6775; Chun-Hui Wang 0000-0003-0370-4989; Bing-Yong Zhang 0000-0003-4980-7246; Hai-Xing Jiang 0000-0002-7941-856X; Yan Xu 0000-0002-4469-3924; Xiu-Li Zuo 0000-0002-2942-1744; Shi-Gang Ding 0000-0002-0831-0965; Rong Lin 0000-0002-5736-7626; Chun-Xiao Chen 0000-0001-7536-1191; Jing-Nan Li 0000-0003-4900-0418.

S-Editor: Chen YL L-Editor: A P-Editor: Zheng XM

#### REFERENCES

- 1 Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153: 420-429 [PMID: 28456631 DOI: 10.1053/j.gastro.2017.04.022]
- Hunt RH, Camilleri M, Crowe SE, El-Omar EM, Fox JG, Kuipers EJ, Malfertheiner P, McColl KE, Pritchard DM, Rugge M, Sonnenberg A, 2 Sugano K, Tack J. The stomach in health and disease. Gut 2015; 64: 1650-1668 [PMID: 26342014 DOI: 10.1136/gutjnl-2014-307595]
- Du Y, Bai Y, Xie P, Fang J, Wang X, Hou X, Tian D, Wang C, Liu Y, Sha W, Wang B, Li Y, Zhang G, Shi R, Xu J, Huang M, Han S, Liu J, 3 Ren X, Wang Z, Cui L, Sheng J, Luo H, Zhao X, Dai N, Nie Y, Zou Y, Xia B, Fan Z, Chen Z, Lin S, Li ZS; Chinese Chronic Gastritis Research group. Chronic gastritis in China: a national multi-center survey. BMC Gastroenterol 2014; 14: 21 [PMID: 24502423 DOI: 10.1186/1471-230X-14-21
- Sipponen P, Price AB. The Sydney System for classification of gastritis 20 years ago. J Gastroenterol Hepatol 2011; 26 Suppl 1: 31-34 4 [PMID: 21199511 DOI: 10.1111/j.1440-1746.2010.06536.x]
- Malfertheiner P, Peitz U. The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia. Gut 2005; 5 54 Suppl 1: i13-i20 [PMID: 15711003 DOI: 10.1136/gut.2004.041533]
- 6 Tatsuta M, lishi H, Okuda S. Relationship of erosive gastritis to the acid secreting area and intestinal metaplasia, and the healing effect of pirenzepine. Gut 1987; 28: 561-565 [PMID: 3297938 DOI: 10.1136/gut.28.5.561]
- Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity. Gastroenterology 2017; 152: 1656-1670 [PMID: 28192107 DOI: 7 10.1053/i.gastro.2016.12.052]
- Nahon S, Nouel O, Hagège H, Cassan P, Pariente A, Combes R, Kerjean A, Doumet S, Cocq-Vezilier P, Tielman G, Paupard T, Janicki E, 8 Bernardini D, Antoni M, Haioun J, Pillon D, Bretagnolle P; Groupe des Hémorragies Digestives Hautes de l'Association Nationale des Hépatogastroentérologues des hôpitaux Généraux. Favorable prognosis of upper-gastrointestinal bleeding in 1041 older patients: results of a prospective multicenter study. Clin Gastroenterol Hepatol 2008; 6: 886-892 [PMID: 18524686 DOI: 10.1016/j.cgh.2008.02.064]
- Guslandi M. Erosive gastritis--does acid matter? Gut 1987; 28: 1321-1322 [PMID: 3678962 DOI: 10.1136/gut.28.10.1321-a] 9
- 10 Du Y, Li Z, Zhan X, Chen J, Gao J, Gong Y, Ren J, He L, Zhang Z, Guo X, Wu J, Tian Z, Shi R, Jiang B, Fang D, Li Y. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci 2008; 53: 2886-2895 [PMID: 18288617 DOI: 10.1007/s10620-007-0180-z]
- Miller TA. Stress erosive gastritis: what is optimal therapy and who should undergo it? Gastroenterology 1995; 109: 626-628 [PMID: 7615216 11 DOI: 10.1016/0016-5085(95)90356-9]
- Tanigawa T, Watanabe T, Higuchi K, Tominaga K, Fujiwara Y, Oshitani N, Tarnawski AS, Arakawa T. Long-term use of nonsteroidal anti-12 inflammatory drugs normalizes the kinetics of gastric epithelial cells in patients with Helicobacter pylori infection via attenuation of gastric mucosal inflammation. J Gastroenterol 2009; 44 Suppl 19: 8-17 [PMID: 19148787 DOI: 10.1007/s00535-008-2287-1]
- Bini EJ, Rajapaksa RC, Weinshel EH. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol 13 2005; **100**: 1586-1592 [PMID: 15984986 DOI: 10.1111/j.1572-0241.2005.41979.x]
- Fang JY, Du YQ, Liu WZ, Ren JL, Li YQ, Chen XY, Lv NH, Chen YX, Lv B; Chinese Society of Gastroenterology, Chinese Medical 14 Association. Chinese consensus on chronic gastritis (2017, Shanghai). J Dig Dis 2018; 19: 182-203 [PMID: 29573173 DOI: 10.1111/1751-2980.12593
- Toljamo K, Niemelä S, Karvonen AL, Karttunen R, Karttunen TJ. Histopathology of gastric erosions. Association with etiological factors and 15 chronicity. Helicobacter 2011; 16: 444-451 [PMID: 22059395 DOI: 10.1111/j.1523-5378.2011.00871.x]
- 16 Kinoshita Y, Chiba T; FUTURE study group. Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study. J Gastroenterol 2012; 47: 377-386 [PMID: 22183857 DOI: 10.1007/s00535-011-0503-x]
- Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. Lancet 2020; 396: 1689-1702 [PMID: 33049222 DOI: 17 10.1016/S0140-6736(20)30469-4
- Potter MDE, Talley NJ. Editorial: new insights into the global prevalence of uninvestigated and functional dyspepsia. Aliment Pharmacol Ther 18 2020; 52: 1407-1408 [PMID: 33105984 DOI: 10.1111/apt.16059]
- 19 Holtmann GJ, Talley NJ. Inconsistent symptom clusters for functional gastrointestinal disorders in Asia: is Rome burning? Gut 2018; 67:



1911-1915 [PMID: 29921653 DOI: 10.1136/gutjnl-2017-314775]

- Sakamoto C, Ogoshi K, Saigenji K, Narisawa R, Nagura H, Mine T, Tada M, Umegaki E, Maekawa T, Maekawa R, Maeda K. Comparison of 20 the effectiveness of geranylgeranylacetone with cimetidine in gastritis patients with dyspeptic symptoms and gastric lesions: a randomized, double-blind trial in Japan. Digestion 2007; 75: 215-224 [PMID: 17971666 DOI: 10.1159/000110654]
- Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of 21 Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353-1367 [PMID: 26187502 DOI: 10.1136/gutjnl-2015-309252]
- Chen Q, Lu H. Kyoto global consensus report on Helicobacter pylori gastritis and its impact on Chinese clinical practice. J Dig Dis 2016; 17: 22 353-356 [PMID: 27164026 DOI: 10.1111/1751-2980.12358]
- Yüksel O, Köklü S, Başar O, Yüksel I, Akgül H. Erosive gastritis mimicking watermelon stomach. Am J Gastroenterol 2009; 104: 1606-1607 23 [PMID: 19491883 DOI: 10.1038/ajg.2009.108]





### Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

